TARS Q3 2021 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M94.8% margin

Operating Income

-$16M-1266.5% margin

Net Income

-$16M-1265.9% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

-94.4%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$190M

Total Liabilities

$11M

Stockholders' Equity

$179M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$16M	-$10M	-54.9%
Net Income	-$16M	-$10M	-54.8%

Revenue Segments

License and Service

$708,00054%

Collaboration

$532,00041%

License And Collaboration

$65,0005%